OS Therapies net loss widens to $19.03 million in FY26 first half; revenue remains no revenue
Reuters2026/08/14 21:05- OS Therapies posted a GAAP net loss of USD 19.03 million for the six months ended June 30, 2026, widening from USD 8.41 million.
- Operating loss widened to USD 18.74 million from USD 9.84 million, with no revenue reported in either period.
- R&D spending more than doubled to USD 13.43 million from USD 3.81 million, due to higher Phase IIb trial vendor costs, partly offset by a USD 1.96 million VAT receivable.
- G&A expense fell 11.8% to USD 5.32 million from USD 6.03 million; cash was USD 200,000 at June 30, 2026.
- Recent financing included USD 4.8 million net proceeds from an April registered direct offering; OS Therapies raised about USD 4.7 million net in an Aug. 10 private placement.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Colgate-Palmolive (CL.US) plans to sell part of its personal care brands, with a total transaction amount possibly exceeding 1.1 billions USD.
According to sources familiar with the matter, Colgate is exploring the sale of some of its mass-market personal care brands. The company currently plans to divest only a few brands within its personal care business, and the combined sale price may exceed 1 billion dollars.

EdiliziAcrobatica announces shareholder meeting notice

Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.